Description
Key facts
Detection method:Colorimetric,
Sample types:Citrate plasma, Heparin Plasma, Serum,
Reacts with:Human,
Assay type:Indirect,
Assay Platform:Microplate
Product details:
Abcam's anti-Mycoplasma pneumoniae IgM Human
in vitro
ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the accurate qualitative measurement of IgM class antibodies against Mycoplasma pneumoniae in Human serum and plasma.
A 96-well plate has been precoated with Mycoplasma pneumoniae antigens to bind cognate antibodies. Controls or test samples are added to the wells and incubated. Following washing, a horseradish peroxidase (HRP) labelled anti-Human IgM conjugate is added to the wells, which binds to the immobilized Mycoplasma pneumoniae-specific antibodies. TMB is then catalyzed by the HRP to produce a blue color product that changes to yellow after adding an acidic stop solution. The density of yellow coloration is directly proportional to the amount of Mycoplasma pneumoniae IgM sample captured in plate.
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Mycoplasma pneumoniae IgM is an immunoglobulin that targets Mycoplasma pneumoniae a bacterium without a cell wall. This IgM antibody plays an important role in identifying the presence of an early infection by this pathogen. Mycoplasma pneumoniae is a small prokaryote with a mass of approximately 200 kilodaltons found mainly in the respiratory tract of infected individuals. ELISA assays can detect Mycoplasma pneumoniae IgM in blood samples. These assays help in diagnosing acute infections especially when patients present with symptoms of respiratory distress.
Biological function summary
Mycoplasma pneumoniae IgM serves as an initial immune response marker during Mycoplasma pneumoniae infection. The IgM antibodies form complexes with antigens of the bacteria facilitating its removal from the body. This IgM response tends to arise early in the infection making it a useful indicator of ongoing or recent infection. The presence of Mycoplasma pneumoniae IgM raises suspicions of respiratory tract infections requiring medical intervention.
Pathways
The immune response involving Mycoplasma pneumoniae IgM aligns with classic immune activation pathways. Its production is triggered during the humoral immune response when the body detects bacterial antigens. The pathways include the complement cascade that enhances the ability of antibodies such as IgM to clear pathogens. During this process proteins like C3 and C4 become activated amplifying the immune defense mechanisms.
Mycoplasma pneumoniae IgM is strongly linked to Mycoplasma pneumonia an atypical respiratory illness. The presence of these antibodies suggests an early or acute phase of the disease guiding clinicians in management strategies. Proteins stimulated by Mycoplasma pneumoniae infection such as C-reactive protein (CRP) often correlate with Mycoplasma pneumoniae IgM providing additional markers for inflammatory responses associated with lung infections.
